Trastuzumab (HLX02) plus Pertuzumab as Dualtarget Neoadjuvant Therapy for HER2-positive Breast Cancer: A Real-World Study

被引：0
作者：
Liu, Yin
Zuo, Wen-Jia
Wang, Ruo-Xi
Wang, Zhong-Hua
Shao, Zhi-Ming
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
基金：
上海市自然科学基金;
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-20
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Neoadjuvant treatment with trastuzumab and pertuzumab plus fulvestrant in older patients with HER2-positive, ER-positive early breast cancer.
    Celis, Juan Jose
    Rodriguez, Vanessa
    Rodriguez, Crismar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 13 - 13
  • [42] BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
    Dang, Chau
    Ewer, Michael S.
    Delaloge, Suzette
    Ferrero, Jean-Marc
    Colomer, Ramon
    de la Cruz-Merino, Luis
    Werner, Theresa L.
    Dadswell, Katherine
    Verrill, Mark
    Eiger, Daniel
    Sarkar, Sriparna
    de Haas, Sanne Lysbet
    Restuccia, Eleonora
    Swain, Sandra M.
    CANCERS, 2022, 14 (11)
  • [43] Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study
    Ewer, Michael
    Baselga, Jose
    Clark, Emma
    Benyunes, Mark
    Ross, Graham
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial
    Xu, Binghe
    Zhang, Qingyuan
    Sun, Tao
    Li, Wei
    Teng, Yue'e
    Hu, Xichun
    Bondarenko, Igor
    Adamchuk, Hryhoriy
    Zhang, Liangming
    Trukhin, Dmytro
    Wang, Shusen
    Zheng, Hong
    Tong, Zhongsheng
    Shparyk, Yaroslav
    Wang, Qingyu
    BIODRUGS, 2021, 35 (03) : 337 - 350
  • [45] Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Yu, Anthony F.
    Manrique, Carlos
    Pun, Shawn
    Liu, Jennifer E.
    Mara, Elton
    Fleisher, Amartin
    Patil, Sujata
    Jones, Lee W.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2016, 21 (04) : 418 - 424
  • [46] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Liu, Lu
    Zhu, Mingzhi
    Wang, Yanyan
    Li, Muhan
    Gu, Yuanting
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [47] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Lu Liu
    Mingzhi Zhu
    Yanyan Wang
    Muhan Li
    Yuanting Gu
    World Journal of Surgical Oncology, 21
  • [48] Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial
    Binghe Xu
    Qingyuan Zhang
    Tao Sun
    Wei Li
    Yue’e Teng
    Xichun Hu
    Igor Bondarenko
    Hryhoriy Adamchuk
    Liangming Zhang
    Dmytro Trukhin
    Shusen Wang
    Hong Zheng
    Zhongsheng Tong
    Yaroslav Shparyk
    Qingyu Wang
    BioDrugs, 2021, 35 : 337 - 350
  • [49] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [50] Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer
    Wyrwicz, L.
    Rodriguez Sanchez, C. A.
    Sanchez-Rovira, P.
    Lewis, S.
    Sandschafer, D.
    San, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S653 - S653
12345